Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...

Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

Patients who have been treated for heart failure and experience an improvement in their pump function are still at higher ...

Inspra (eplerenone tablets; Pfizer, Inc., New York, NY) is an aldosterone blocker that works by binding at the mineralocorticoid receptor. It has some similarities to the potassium-sparing ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...